Pharmacokinetic and Pharmacologic Variation Between Different Estrogen Products

@article{OConnell1995PharmacokineticAP,
  title={Pharmacokinetic and Pharmacologic Variation Between Different Estrogen Products},
  author={Mary Beth O'Connell},
  journal={The Journal of Clinical Pharmacology},
  year={1995},
  volume={35}
}
  • M. O'Connell
  • Published 1995
  • Chemistry, Medicine
  • The Journal of Clinical Pharmacology
Due to the complex nature of endogenous and exogenous hormone concentrations, formation, and metabolism and assay complexity, the pharmacokinetics of estrogens are difficult to study. Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first‐pass) metabolism. High concentrations of estrone are achieved with oral administration, whereas higher concentrations of estradiol are generally achieved after percutaneous absorption. Although vaginal products (such as… Expand
Pharmacokinetics of estrogen and progesterone in chronic kidney disease.
TLDR
These studies suggest that women with CKD should receive a least a 50% reduction in oral estradiol doses, and knowledge of the concentration effect relationship for the treatment of symptoms of menopause, as well as prevention of osteoporosis, will benefit all postmenopausal women. Expand
The pharmacokinetics and efficacy of different estrogens are not equivalent.
  • R. Ansbacher
  • Medicine
  • American journal of obstetrics and gynecology
  • 2001
TLDR
The studies comparing estrogen formulations are summarized, the differential effects of various estrogen products that promote postmenopausal health are discussed, and the dosage and route of administration are discussed. Expand
Evaluation of Single‐ and Multiple‐Dose Pharmacokinetics of Synthetic Conjugated Estrogens, A (Cenestin®) Tablets: A Slow‐Release Estrogen Replacement Product
A multiple‐dose, placebo‐controlled, randomized pharmacokinetic study was performed in 15 early (i.e., 1–3 years) postmenopausal women to evaluate the single and steady‐state pharmacokinetics ofExpand
Are all estrogens created equal? A review of oral vs. transdermal therapy.
TLDR
Significant differences appear to exist between oral and transdermal estrogens in terms of hormonal bioavailability and metabolism, with implications for clinical efficacy, potential side effects, and risk profile of different hormone therapy options, but neither results nor study designs are uniform. Expand
Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women.
TLDR
The decrease in LH serum concentrations found after the highest dose demonstrates the ability of 8-PN to exert systemic endocrine effects in postmenopausal women. Expand
Hormone replacement therapy in menopausal women: Past problems and future possibilities
TLDR
There is evidence that estriol, by binding preferentially to estrogen receptor-β, may inhibit some of the unwanted effects of estradiol, which is an increasingly popular alternative hormone therapy used for menopausal symptoms. Expand
Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches
Objective A new matrix 17β-estradiol transdermal patch incorporating lauric acid to improve estradiol skin absorption has been designed for hormone replacement therapy. Estradiol pharmacokineticsExpand
A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream
TLDR
After intravaginal application of SCE-A vaginal cream, absorption of estrogens was lower compared with absorption after oral administration, and systemic exposure of equilin, estradiol, and estrone was significantly lower after twice-weekly administration. Expand
Comparison of the transdermal delivery of estradiol from two gel formulations.
TLDR
In vitro percutaneous penetration of estradiol from the formulations through epidermal membranes prepared from excised female human thing skin suggested that the two formulations are bioequivalent at the recommended dose levels. Expand
Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg
TLDR
Estradiol 0.5 mg/norethisterone acetate 0.1 mg, despite being a lower dose than conventional hormones, is a compound, among a few other low-dose options, that can be used in hormone replacement therapy, and has demonstrated its effectiveness, with high tolerability and, apparently, no safety concerns, in a 6-month study. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Pharmacokinetics of estrogen
  • P. Stumpf
  • Medicine
  • Obstetrics and gynecology
  • 1990
TLDR
Clinicians should understand the pharmacokinetics of the various options for replacement therapy and select a course of treatment that is safe, effective, and convenient for the patient. Expand
Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement.
TLDR
The conclusions that levels of circulating estradiol are relevant to efficacy, and that excessively high levels of estrone after oral administration of estrogens merely represents a nonphysiologic precursor or metabolite pattern, are supported. Expand
Biologic effects of transdermal estradiol.
TLDR
Transdermal estradiol can elicit many of the desirable actions of estrogen while avoiding the pharmacologic effects of oral estrogens on hepatic proteins, according to a dose-response study in postmenopausal women. Expand
Biologic effects of equilin sulfate in postmenopausal women.
TLDR
It is concluded that EqS is a potent estrogen that contributes significantly to the hepatic stimulatory effects of conjugated equine estrogens and provides support for the suggestion that there may be a dissociation in potency between estrogenic effects on liver and bone. Expand
Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol.
TLDR
The purpose of the study was to determine the absolute bioavailability of orally administered E2 in a larger group of women and to assess the inter- and intraindividual variability of basic pharmacokinetic parameters of E2 and metabolically derived E1. Expand
Interactions with oral contraceptives
  • K. Fotherby
  • Medicine
  • American journal of obstetrics and gynecology
  • 1990
TLDR
Evidence suggests that some anticonvulsant, antibiotic, and antibacterial drugs may reduce the efficacy of oral contraceptives and both pharmacokinetic and pharmacodynamic interactions are important. Expand
Antipyrine Pharmacokinetics in Women Receiving Conjugated Estrogens
TLDR
Although antipyrine clearance is significantly impaired by oral contraceptives, there is no evidence of altered antipyrines pharmacokinetics from treatment with conjugated estrogens. Expand
Effects of oral contraceptive steroids on acetaminophen metabolism and elimination
TLDR
The data suggest that the increased clearance of acetaminophen from plasma in women taking OC steroids results from increased glucuronidation of the drug, although the mechanism is not known. Expand
Transport of equine estrogens: binding of conjugated and unconjugated equine estrogens with human serum proteins.
TLDR
The results indicate that the equine estrogens bind to SHBG and albumin in a manner similar to that of E1 and E2, and that the low MCR of EqS reported previously may be due to its binding to albumin. Expand
Sustained-release subdermal estradiol implants: a new alternative in estrogen replacement therapy.
TLDR
This study shows that constant release profiles can be achieved with nonbiodegradable estradiol implants and suggests that a single application should give sufficient estrogen substitution for more than a year. Expand
...
1
2
3
4
5
...